Waters Corporation and Prosolia, Inc. Collaborate on DESI

Waters Corporation and Prosolia, Inc. are working together to develop models of Prosolia's DESI Omni SprayTM Ion Source that are compatible with Waters mass spectrometers.

The Prosolia Omni SprayTM Ion Source brings the novel technique, desorption electrospray ionization (DESI), to the laboratory. DESI is a simple, sensitive, gentle, and versatile ionization method, which allows for the direct sampling of surfaces without any sample preparation and under ambient temperature and pressure conditions. This technique is effective for not only small molecules, but also for large molecules such as peptides and proteins. The Omni SprayTM Ion Source has applications in drug discovery, in situ analysis of biological tissues and other fragile surfaces, as well as in homeland security and environmental monitoring.

The initial effort will be to develop an Omni SprayTM Ion Source for the Waters LCT PremierTM XE. This instrument is the market-leading orthogonal acceleration time-of-flight (oa-TOF) benchtop mass spectrometer. The LCT PremierTM XE is an easy-to-use bench top platform with a range of powerful and innovative technologies that provide an unbeatable level of sensitivity, specificity and flexibility in compound identification.

The LCT Premier XE's high sensitivity Z-SprayTM API interface, ion transfer optics and TOF analyzer provides the most sensitive benchtop oa-TOF instrument in its class, giving capability of detecting very low level components with full spectral information. The versatility of the LCT PremierTM XE makes it a perfect platform for developing the DESI source compatible with Waters mass spectrometers. The companies plan that once the design is completed for the LCT PremierTM XE they will quickly adapt the source for other Waters mass spectrometers.

This new model of Omni SprayTM Ion Source will be introduced at the 55th ASMS Conference on Mass Spectrometry being held in Indianapolis on June 3-7, 2007.

Prosolia, Inc. was founded in 2003 to commercialize revolutionary analytical chemistry technologies, developed in the laboratory of Prof. R. Graham Cooks at Purdue University, which enhance and expand the use of mass spectrometry. The company's first product line, Omni SprayTM Ion Source, was introduced in November 2005 and utilizes the novel atmospheric pressure ionization technique, desorption electrospray ionization (DESI). The company has laboratories in Indianapolis and West Lafayette, Indiana and is funded in part by the Indiana 21st Century Research & Technology Fund.

Waters Corporation holds worldwide leading positions in three complementary analytical technologies - liquid chromatography, mass spectrometry and thermal analysis. These markets account for approximately \$5.0 billion of the overall \$20 - \$25 billion analytical instrument market.

For more information, John F. Graves, Prosolia, Inc. +1 317-278-6136, graves@prosolia.com or Brian J. Murphy, Waters Corporation, +1 508-482-2614, brian_j_murphy@waters.com.

Aptuit, Inc. Acquires SSCI

In late October, 2006 Aptuit, Inc. of Greenwich, Connecticut announced that they had acquired SSCI, the leading solid state chemistry company focused on crystallization, characterization and chemistry of solid materials. The acquisition enables Aptuit to leverage SSCI's expertise in solid-state pharmaceutical product development to broaden its service offering for customers. SSCI is located in the Purdue Research Park in West Lafayette, Indiana.

As part of the transaction, Aptuit acquired SSCI's facilities in West Lafayette, Indiana; Atlanta, Georgia; and Oxford, UK, and retains SSCI's approximately 100 employees. SSCI will continue to operate under the SSCI brand for a period of time, but customers will have a seamless transition between the SSCI and Aptuit service offerings.

SSCI CEO, Sally Byrn was named Vice President, Physical and Analytical Chemistry at Aptuit. In addition to new responsibilities for Ms. Byrn, several members of the SSCI management team were named to leadership positions within Aptuit: Richard Ferguson, SSCI's CFO was named Vice President, Treasurer; David Bertolino became Senior Director, Human Resources; and Daniel Pannell is now Senior Director, Physical and Analytical Chemistry. Pat Stahly, Ph.D. remains SSCI's Chief Operating Officer.

For more about Aptuit, visit www.aptuit.com.

George W. Sledge Receives 2006 Brinker Award

Indiana University Cancer Center breast cancer specialist George W. Sledge Jr., M.D. has been honored with the 2006 Brinker Award for Scientific Distinction by the Susan G. Komen Breast Cancer Foundation at the 29th Annual San Antonio Breast Cancer Symposium.

The Komen Brinker Award was established in 1992 to recognize leading scientists for their significant work in advancing research concepts or clinical application in the fields of breast cancer research, screening or treatment.

Dr Sledge, who is the the Ballve-Lantero Professor of Oncology and professor of medicine at Indiana University, received the 2006 award for clinical research. Evan Simpson, Ph.D., director of the Price Henry's Institute of Medical Research in Melbourne, Australia, was the 2006 award recipient for basic science.

Dr. Sledge was one of the first researchers to recognize the importance of angiogenesis in breast cancer tumor growth and has been a leader in the application of anti-angiogenesis therapies designed to prevent the development of new blood vessels in human cancers. His work in recent years has focused on novel biologic therapies for breast cancer.

Source: Indiana University Cancer Center

2007 Charles N. Reilley Award

This year's Reilley Award was presented to George S. Wilson, Higuchi distinguished Professor of Chemistry and Pharmaceutical Chemistry at the University of Kansas, on February 28, during The Pittsburgh Conference in Chicago. Professor Wilson is internationally recognized for his pioneering works in bioelectroanalytical chemistry and has made significant contributions in all three areas of theory, instrumentation, and applications of electroanalysis. A few examples are his early work on the electrochemistry of porphyrins as models for electron transfer in cytochromes and his pioneering work on the use of spectroelectrochemistry for the study of electron transfer reactions in biomolecules. He has developed sensitive electrochemical immunoassay and enzyme-based sensors. He pioneered much of the work on in vivo subcutaneous sensors for blood glucose monitoring. His current research includes redox biochemistry, in vivo measurements with biosensors, analysis of chromosome structure, and development of analytical reagents based on biological recognition.

The Reilley Award is sponsored each year by BASi (Bioanalytical Systems, Inc.) and presented by the Society for Electroanalytical Chemistry (SEAC).

Meetings and Conferences

5th International Symposium on Microdialysis in Drug Research and Development

April 26-28, 2007, Leiden, The Netherlands (A post-satellite to the Pharmaceutical Sciences World Congress, April 22-25, 2007, Amsterdam)

This Symposium will focus on discussions and exchange of knowledge about the latest developments of the role and potential of in vivo microdialysis complementary to other techniques and approaches to increase drug candidate selection efficiency, with the following workshops:

- Methodological Advances and Considerations in Monitoring the Extracellular Space
- Preclinical and Clinical Pharmacokinetics and Target Site Distribution
- Pharmacokinetic-Pharmacodynamic Correlations
- Monitoring Biomarkers and Drug Penetration in Disease Conditions

Organizing Committee: Elizabeth CM de Lange, Chair; Meindert Danhof; Martha van der Ham and Erik de Vries. More information is available at www.lacdr.nl

KEEPING PACE WITH YOUR RESEARCH



CARDIOMONITOR

New from BASi Vetronics, CardioMonitor is the ideal tool for monitoring the heart rate of your animal research subject during probe implantation surgery and recovery—especially important during prolonged anesthesia.

- Heart rate display on large LCD screen

Flashing red LED and audible tone provide additional cues

- Monitors post-operative recovery

Sensitivity adjustment for use with animals ranging from rodents to horses

Compact and easy to use (runs from 9V battery)

- Ideal for use in laboratory or post-operative recovery cage

vetronics

800-654-6327 • FAX 765-742-6699 • vetronics@bioanalytical.com • www.vetronics.net

Culex® Automated Pharmacology System

In vivo sampling? Do it in your sleep. Really!

The Culex APS operates unattended 24/7. You as the user define collection times and sample volumes with Culex software interface. Set it and let it go. Have dinner, go to the movies, watch your children play soccer, get a good night's sleep, and all the while your Culex is dosing, sampling and simultaneously monitoring behavior and performing microdialysis for PK/PD correlations. That and much more.

How can you expect good data if your subject is stressed?

Imagine your reaction if some gigantic creature picked you up and forced some nasty-tasting stuff down your throat. How would your body react? The effects of stress on animals (of all species and sizes) are well documented. Think about it. We did. Research has shown that the stress associated with conventional blood sampling from rodents often has substantial effects on neurotransmitters, hormones, behavior and pharmacokinetic parameters. Thus, we determined that human handling of lab rats (and other animal subjects) results in inferior quality data.

Relax . . .

We found a way to sample freelymoving awake animals (rats, guinea pigs and, yes, even mice) without causing data-distorting stress. An implanted catheter is affixed to a tether assembly mounted to a counter-balanced arm that keeps the catheter from the animal's reach and view. The animal is free to move around inside a movementresponsive cage called a Raturn®, eliminating need for a liquid swivel. Once the animal is installed, dosing via IV, gastric or duodenal catheters can occur, and infusions, both bolus and continuous, can be programmed with an optional accessory, the Empis. All this is accomplished automatically, with no human-animal interaction.

It's about better science.

Multiple experiments can be performed in parallel, which means using fewer animals.

Data gathered via Culex are more accurate, precise and cost-effective, and offer unprecedented ability to correlate PK/PD results directly. For example, Culex can simultaneously monitor pharmacokinetics, neurotransmitter pharmacodynamics, rotational and rearing behavior, metabolism (urine and feces), and even

electrocardiograms. Researchers can now conduct humane, pain-free complete bioavailability studies using conscious, freely-moving rodents.

It's about time!

Better data in less time is a constant goal of the pharmaceutical industry. Experiments performed in parallel rather than in a series is one way to meet this goal. Having studies progress 24/7 without human involvement is cost-effective and

also saves time. And it's done with the utmost confidence that doses were delivered on time, all the samples were taken and no animals were missed. These, along with dose size, length of sampling time, and more, are completed automatically and detailed reports are produced. After a relaxing evening, the researcher returns to the lab the next morning to find a comprehensive report of everything that took place the night before. It's about time!



Eliminate stress in subjects and scientists.



In your lab or ours.
Learn more now: www.culex.net



Pharmaceutical TECHNOLOGY, INC.

Dr. Matharu 1212 Rappel Drive Bloomington, IN 47404-1702 812-330-8121 fax: 812-330-8363 info@kppt.com www.kppt.com

cGMP Facility

- Formulation Development
- Clinical Manufacturing and Packaging
- Analytical and ICH Stability
- All Types of Dosage Forms
- Fastest Turn-Around



www.indianacaps.com



APPLYING PROTEIN TECHNOLOGIES TO BIOLOGICAL PROBLEMS

INCAPS is a fee-for-service Contract Research Organization specializing in:

- Protein Analysis
- Proteomics
- Technology Validation
- Biomarker Discovery
- Biomarker Consortia

Please contact us to see how we can be of service.

For more information, please contact:
Lauri Caviston
Phone: 203.623.4706
Icaviston@indianacaps.com

351 West 10th Street Suite 350 Indianapolis, IN 46202